Literature DB >> 973959

beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

W H Aellig.   

Abstract

The beta-adrenoceptor blocking activities of pindolol and propranolol have been investigated in healthy male volunteers. Pindolol was about forty times more potent than propranolol in reducing isoprenaline-induced tachycardia. Pindolol (5 mg) and propranolol (u99 mg) were approximately equiactive in reducing exercise-induced tachycardia, 2 h after oral administration. The duration of action of pindolol is significantly longer than that of propranolol; 24 h after pindolol (kmg), 36+/-5% of the masimum effect were still present, and after propranolol (100 mg) 16+/-4% remained. Despite the long duration of action of pindolol, there was no evidence for cumulation during oral administration of 5 mg t.d.s. for 5 days.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973959      PMCID: PMC1428873          DOI: 10.1111/j.1365-2125.1976.tb00600.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man.

Authors:  R Gugler; W Höbel; G Bodem; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

2.  Pindolol in hypertension: twice-daily versus thrice-daily dosage.

Authors:  H J Waal-Manning; A J Wood
Journal:  Med J Aust       Date:  1975-08-16       Impact factor: 7.738

3.  The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram.

Authors:  B N Prichard; W H Aellig; G A Richardson
Journal:  Postgrad Med J       Date:  1970-11       Impact factor: 2.401

4.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Prolonged action of pindolol.

Authors:  W H Aellig; K Saameli
Journal:  Br Med J       Date:  1973-05-12

6.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol.

Authors:  W H Aellig
Journal:  Br J Pharmacol       Date:  1973-03       Impact factor: 8.739

Review 8.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

9.  Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man.

Authors:  R C Hill; P Turner
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739

  9 in total
  35 in total

1.  Acute changes in forearm haemodynamics produced by cigarette smoking in healthy normotensive non-smokers are not influenced by propranolol or pindolol.

Authors:  P Brunel; X Girerd; S Laurent; B Pannier; M Safar
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.

Authors:  J Meier; E Nüesch
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects.

Authors:  J G Maconochie; E P Woodings; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

4.  Responses to exercise in the heat related to measures of hypothalamic serotonergic and dopaminergic function.

Authors:  Mathew W Bridge; Andrew S Weller; Mark Rayson; David A Jones
Journal:  Eur J Appl Physiol       Date:  2003-04-09       Impact factor: 3.078

5.  Left ventricular function and beta-blockers: does intrinsic sympathomimetic activity have any influence during chronic therapy?

Authors:  R J Northcote; M B Cooke; D Ballantyne
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

6.  Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 7.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

8.  Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment.

Authors:  S Mann; M W Craig; V Balasubramanian; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

9.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol.

Authors:  W Reid; D J Ewing; J D Harry; H J Smith; J M Neilson; B F Clarke
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.